Azurrx Biopharma Inc., of Brooklyn, N.Y., is selling 4.16 million shares of its common stock at $2.50 per share, grossing the company $10.4 million. Azurrx plans to use the capital to continue clinical development of MS-1819, its recombinant lipase for exocrine pancreatic insufficiency, advancing its preclinical programs for AZX-1103 and for other general corporate purposes and capital expenditures.